At Hard-Hit Gene Therapy Company Freeline, CEO Believes A Turnaround Is Possible

Readout In Hemophilia B Expected Soon

 
• By Andrew McConaghie

Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.

Biotech
Gene therapy companies have seen their share prices fall by 65% on average over the last 12 months, making them one of the worst hit specialities in biotech. • Source: Shutterstock

More from Business

More from Scrip